+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Chemotherapy Induced Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Pheochromocytoma - Pipeline Insight, 2024 - Product Thumbnail Image

Pheochromocytoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 280 Pages
  • Global
From
Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
AXL Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 80 Pages
  • Global
From
Tie-2 modulators - Pipeline Insight, 2024 - Product Thumbnail Image

Tie-2 modulators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
4-1BB receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

4-1BB receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more